Prescription Pattern Analysis of Type II Diabetes Mellitus Inpatients and Associated Co-Morbidities
Background: The present study was planned to assess the prescription pattern analysis of Type II Diabetes Mellitus and associated co-morbidities. As per WHO, the worldwide prevalence of DM will reach 366 million by 2030. Evaluating drug prescription pattern is a major aspect of patient care, which is used as a measure of the quality of care provided. Objectives: Primary objectives of the study were to highlight the current prescription pattern trends in patients having diabetes mellitus with or without other co-morbid conditions, to ensure safety and rational use of prescribed regimen. And the secondary objectives of the study were to analyse the demographic information of the enrolled patients and also to identify and analyse the prescriptions with polypharmacy. Materials and Methods: A prospective observational study was conducted to analyse the prescribing pattern of anti-diabetic drugs. The study incorporated 100 Type II DM inpatients having comorbid conditions. The study has been conducted with the help of WHO prescribing indicator scale. It is used to analyse drug class, generic and branded drugs, fixed dose combination and dosage form. Patient data was collected and medical data records were analysed daily till discharge from hospital. Results: It was found that most of the drugs have been prescribed are purely from Karnataka Essential Medicine list (KEML). And percentages of medicines prescribed on their generic name were 76%. About 51% of patients were treated only with oral hypoglycemic agents. Whereas, 38% were treated with Insulin and 11% were treated with both oral hypoglycemic agents and Insulin. Conclusion: Improved rational use of prescription by using Essential Medicine List (EML).And also ensured the appropriateness of prescription by using WHO scale. Several Adverse Drug Reactions (ADR)have been reported and which leads to improved prescription pattern.
Keywords: Type II Diabetes Mellitus, Prescribing Indicator, Co-Morbidities.
2. Maitra A , Abbas A K, Kumar V, Fausto N, The Endocrine system. In: Pathologic basis of disease. 2005; 1156-1226.
3. Mahmood M, Reddy RC. Prescription Pattern Analysis of Antidiabetic Drug in Diabetes Mellitus and Associated Co-morbidities: Clin. Invest.(Lond.); 2017; 8(1);5-12.
4. Anastasios Tentolouris, Ioanna Eleftheriadou, Kostas Athanasakis, John Kyriopoulos, Diamantis I. Tsilimigras, Pinelopi Grigoropoulou, John Doupis, Prevalence of diabetes mellitus as well as cardiac and other main comorbidities in a representative sample of the adult Greek population in comparison with general population.2018;1-8.
5. Rashid M, Anandhasayanam KM, Kannan S. Prevalence of co-morbidities in Type 2 Diabetes Mellitus Patients,The Awareness Level and the Impact of Pharmacist’s Patient Education Program.2015; 4(5);11-20.
6. Campbell R.K. Type II diabetes: where we are today. An overview of disease burden,current treatments and treatment strategies. JLM Pharmacist Assoc.2009;49(suppl):S3-S9;7-14.
7. Fenstei A R, The pre-therapeutic classification of co-morbidity in chronic disease. Jchron Dis.1970; 23:455-468.
8. Lechauncy D. Woodard, Urech T, Landrum CR. The impact of comorbidity type on measures of quality for diabetes care. Med care. 2011; 49:605-610.
9. Rowan JA, Hagne WM, Gao W, Battin MR, Moore M P. For the Mig Trial Investigators,Metformin versus insulin for the treatment of gestational diabetes. 2008; 358-552.
10. Dipiro JT, Talbert RL, Gary CY, Matzke GR, Wells BJ, Michael P. Pharmacotherapy:A pathophysiologic approach. 2008; 1205-41.
11. Manjusha S, Amit M, Ronak S, A study on prescribing pattern and potential drug-drug interaction in Type 2 diabetic mellitus inpatients. 2013; 1-2.
12. Kevin M Pantalone, Todd M Hobbs,Brian J Wells.BMJ Open Diabetes Research And Care,Clinical characteristics, complications, comorbidities and treatment patterns among patients with Type 2 diabetes mellitus in a large integrated health system. 2015; 5-6.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).